Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins
Reduction of LDL-cholesterol concentration in serum, blocking the isoprenylation of GTPases and the activation of myocyte-protective enzyme systems are three mechanisms that currently explain the lipid and non-lipid effects of statins. However, the decrease of LDL-cholesterol, the reduction of infla...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.4061/2011/904742 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850175677639163904 |
|---|---|
| author | Enrique C. Morales-Villegas Germano Di Sciascio Carlo Briguori |
| author_facet | Enrique C. Morales-Villegas Germano Di Sciascio Carlo Briguori |
| author_sort | Enrique C. Morales-Villegas |
| collection | DOAJ |
| description | Reduction of LDL-cholesterol concentration in serum, blocking the isoprenylation of GTPases and the activation of myocyte-protective enzyme systems are three mechanisms that currently explain the lipid and non-lipid effects of statins. However, the decrease of LDL-cholesterol, the reduction of inflammation biomarkers and even the atheroregresion, as surrogate effects to the mechanisms of action of statins would be irrelevant if not accompanied by a significant decrease in the incidence of cardiovascular events. Statins like no other pharmacological group have proven to reduce the incidence of cardiovascular events and prolong life in any clinical scenario. This article review the basic and clinical evidence that support a new indication for HMG-CoA reductase inhibitors “pharmacological myocardial preconditioning before anticipated ischemia” or hyperacute use of statins in subjects with any coronary syndrome eligible for elective, semi-urgent or primary percutaneous coronary intervention: ARMYDA-Original, NAPLES I-II, ARMYDA-ACS, ARMYDA-RECAPTURE, Non-STEMI-Korean, Korean-STEMI trials. |
| format | Article |
| id | doaj-art-ba842b73da974499ad6ece4f9e3f2eab |
| institution | OA Journals |
| issn | 2090-0392 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-ba842b73da974499ad6ece4f9e3f2eab2025-08-20T02:19:26ZengWileyInternational Journal of Hypertension2090-03922011-01-01201110.4061/2011/904742904742Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of StatinsEnrique C. Morales-Villegas0Germano Di Sciascio1Carlo Briguori2Centro de Investigación Cardiometabólica, Quinta Avenida 702-210, Frac. Agricultura, Aguascalientes, 20234 México, AGS, MexicoUniversità Campus Bio-Medico di Roma, 00128 Rome, ItalyClinica Mediterranea, Laboratorio di Emodinamica e Cardiologia Interventistica, 80122 Naples, ItalyReduction of LDL-cholesterol concentration in serum, blocking the isoprenylation of GTPases and the activation of myocyte-protective enzyme systems are three mechanisms that currently explain the lipid and non-lipid effects of statins. However, the decrease of LDL-cholesterol, the reduction of inflammation biomarkers and even the atheroregresion, as surrogate effects to the mechanisms of action of statins would be irrelevant if not accompanied by a significant decrease in the incidence of cardiovascular events. Statins like no other pharmacological group have proven to reduce the incidence of cardiovascular events and prolong life in any clinical scenario. This article review the basic and clinical evidence that support a new indication for HMG-CoA reductase inhibitors “pharmacological myocardial preconditioning before anticipated ischemia” or hyperacute use of statins in subjects with any coronary syndrome eligible for elective, semi-urgent or primary percutaneous coronary intervention: ARMYDA-Original, NAPLES I-II, ARMYDA-ACS, ARMYDA-RECAPTURE, Non-STEMI-Korean, Korean-STEMI trials.http://dx.doi.org/10.4061/2011/904742 |
| spellingShingle | Enrique C. Morales-Villegas Germano Di Sciascio Carlo Briguori Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins International Journal of Hypertension |
| title | Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins |
| title_full | Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins |
| title_fullStr | Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins |
| title_full_unstemmed | Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins |
| title_short | Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins |
| title_sort | statins cardiovascular risk reduction in percutaneous coronary intervention basic and clinical evidence of hyperacute use of statins |
| url | http://dx.doi.org/10.4061/2011/904742 |
| work_keys_str_mv | AT enriquecmoralesvillegas statinscardiovascularriskreductioninpercutaneouscoronaryinterventionbasicandclinicalevidenceofhyperacuteuseofstatins AT germanodisciascio statinscardiovascularriskreductioninpercutaneouscoronaryinterventionbasicandclinicalevidenceofhyperacuteuseofstatins AT carlobriguori statinscardiovascularriskreductioninpercutaneouscoronaryinterventionbasicandclinicalevidenceofhyperacuteuseofstatins |